Percentage of Revenue from Significant Customers (Detail) (Sales)	3 Months Ended
Mar. 31, 2014	Mar. 31, 2013
BioMarin Pharmaceutical, Inc.
Revenue, Major Customer [Line Items]
Concentration risk percentage	12.00%
Orencia Royalties from Bristol
Revenue, Major Customer [Line Items]
Concentration risk percentage		24.00%
Bioprocessing Customer A
Revenue, Major Customer [Line Items]
Concentration risk percentage	40.00%	38.00%
Bioprocessing Customer B
Revenue, Major Customer [Line Items]
Concentration risk percentage	22.00%	12.00%
Bioprocessing Customer C
Revenue, Major Customer [Line Items]
Concentration risk percentage	14.00%	15.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration